Selected research
Industry Research
Metabotropic Glutamate Receptor 3 Industry Research Report 2026
Market perspective
The global Metabotropic Glutamate Receptor 3 market was valued at US$ million in 2025 and is projected to reach US$ million by 2032, implying a CAGR of % over 2026–2032.
North America: the Metabotropic Glutamate Receptor 3 market is projected to increase from US$ million in 2026 to US$ million by 2032, reflecting a CAGR of % over 2026–2032. Europe: the Metabotropic Glutamate Receptor 3 market is projected to rise from US$ million in 2026 to US$ million by 2032, registering a CAGR of % over 2026–2032. Asia Pacific: the Metabotropic Glutamate Receptor 3 market is expected to grow from US$ million in 2026 to US$ million by 2032, at a CAGR of % over 2026–2032. Leading global service providers of Metabotropic Glutamate Receptor 3 include Eli Lilly and Company, Prexton Therapeutics SA, Domain Therapeutics SA, Denovo Biopharma LLC, Aevi Genomic Medicine Inc and Addex Therapeutics Ltd, among others; in 2025, the top three vendors together accounted for approximately % of global revenue.
Report Scope
Read the full market overview
This report quantifies the global Metabotropic Glutamate Receptor 3 market in terms of revenue (US$ million) and, where applicable, service volume (K Units), using 2024 as the base year and providing annual historical and forecast data for 2021–2032.
It standardizes definitions of service Types and end-use Applications, harmonizes provider attribution, and delivers comparable time series by company, Type, Application, and region or country, including indicative price bands (US$/K Units) and concentration ratios (CR5/CR10). Outputs are intended to support service design, budgeting, capacity planning, and benchmarking for providers, platforms, channel partners, and investors; the report also reviews technology shifts and notable service innovations relevant to Metabotropic Glutamate Receptor 3.
Key Companies & Market Share Insights
This section profiles leading service providers with 2021–2025 results and a 2026–2032 outlook—covering revenue, market share, price bands, service portfolio and client mix, regional and channel mix, and key developments (M&A, network expansion, certifications). It also provides global revenue, average price, and—where applicable—volume metrics by provider, and calculates CR5/CR10 and rank changes to support comparative benchmarking.
Metabotropic Glutamate Receptor 3 Market by Company
Eli Lilly and Company
Prexton Therapeutics SA
Domain Therapeutics SA
Denovo Biopharma LLC
Aevi Genomic Medicine Inc
Addex Therapeutics Ltd
Metabotropic Glutamate Receptor 3 Segment by Type
DT-010991
LY-3020371
VU-0092273
Others
Metabotropic Glutamate Receptor 3 Segment by Application
Autism
Chronic Pain
Glioma
Others
Metabotropic Glutamate Receptor 3 Segment by Region
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Spain
Russia
Netherlands
Nordic Countries
Asia-Pacific
China
Japan
South Korea
India
Australia
China Taiwan
Southeast Asia
South America
Mexico
Brazil
Argentina
Middle East & Africa
Saudi Arabia
Israel
United Arab Emirates
Turkey
Iran
Egypt
Key Drivers & Barriers
High-impact rendering factors and drivers have been studied in this report to aid the readers to understand the general development. Moreover, the report includes restraints and challenges that may act as stumbling blocks on the way of the players. This will assist the users to be attentive and make informed decisions related to business. Specialists have also laid their focus on the upcoming business prospects.
Reasons to Buy This Report
1. This report will help the readers to understand the competition within the industries and strategies for the competitive environment to enhance the potential profit. The report also focuses on the competitive landscape of the global Metabotropic Glutamate Receptor 3 market, and introduces in detail the market share, industry ranking, competitor ecosystem, market performance, new product development, operation situation, expansion, and acquisition. etc. of the main players, which helps the readers to identify the main competitors and deeply understand the competition pattern of the market.
2. This report will help stakeholders to understand the global industry status and trends of Metabotropic Glutamate Receptor 3 and provides them with information on key market drivers, restraints, challenges, and opportunities.
3. This report will help stakeholders to understand competitors better and gain more insights to strengthen their position in their businesses. The competitive landscape section includes the market share and rank (in volume and value), competitor ecosystem, new product development, expansion, and acquisition.
4. This report stays updated with novel technology integration, features, and the latest developments in the market
5. This report helps stakeholders to gain insights into which regions to target globally
6. This report helps stakeholders to gain insights into the end-user perception concerning the adoption of Metabotropic Glutamate Receptor 3.
7. This report helps stakeholders to identify some of the key players in the market and understand their valuable contribution.
Chapter Outline
Chapter 1: Research objectives, research methods, data sources, data cross-validation;
Chapter 2: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 3: Provides the analysis of various market segments product types, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 4: Provides the analysis of various market segments application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 5: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 6: Detailed analysis of Metabotropic Glutamate Receptor 3 companies’ competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 7, 8, 9, 10, 11: North America, Europe, Asia Pacific, South America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 12: Provides profiles of key players, introducing the basic situation of the main companies in the market in detail, including revenue, gross margin, product introduction, recent development, etc.
Chapter 13: The main points and conclusions of the report.
More report detail
Tables and figures
Scope & coverage.
Types
- DT-010991
- LY-3020371
- VU-0092273
- Others
Applications
- Autism
- Chronic Pain
- Glioma
- Others
Companies covered
- Eli Lilly and Company
- Prexton Therapeutics SA
- Domain Therapeutics SA
- Denovo Biopharma LLC
- Aevi Genomic Medicine Inc
- Addex Therapeutics Ltd
Inside the report.
1 Preface
- 1.1 Scope of Report
- 1.2 Reasons for Doing This Study
- 1.3 Research Methodology
- 1.4 Research Process
- 1.5 Data Source
- 1.5.1 Secondary Sources
- 1.5.2 Primary Sources
2 Market Overview
- 2.1 Product Definition
- 2.2 Metabotropic Glutamate Receptor 3 by Type
- 2.2.1 Market Value Comparison by Type (2021 VS 2025 VS 2032)
- 2.2.2 DT-010991
- 2.2.3 LY-3020371
- 2.2.4 VU-0092273
- 2.2.5 Others
- 2.3 Metabotropic Glutamate Receptor 3 by Application
- 2.3.1 Market Value Comparison by Application (2021 VS 2025 VS 2032)
- 2.3.2 Autism
- 2.3.3 Chronic Pain
- 2.3.4 Glioma
- 2.3.5 Others
- 2.4 Assumptions and Limitations
3 Metabotropic Glutamate Receptor 3 Breakdown Data by Type
- 3.1 Global Metabotropic Glutamate Receptor 3 Historic Market Size by Type (2021-2026)
- 3.2 Global Metabotropic Glutamate Receptor 3 Forecasted Market Size by Type (2027-2032)
4 Metabotropic Glutamate Receptor 3 Breakdown Data by Application
- 4.1 Global Metabotropic Glutamate Receptor 3 Historic Market Size by Application (2021-2026)
- 4.2 Global Metabotropic Glutamate Receptor 3 Forecasted Market Size by Application (2027-2032)
5 Global Growth Trends
- 5.1 Global Metabotropic Glutamate Receptor 3 Market Perspective (2021-2032)
- 5.2 Global Metabotropic Glutamate Receptor 3 Growth Trends by Region
- 5.2.1 Global Metabotropic Glutamate Receptor 3 Market Size by Region: 2021 VS 2025 VS 2032
- 5.2.2 Metabotropic Glutamate Receptor 3 Historic Market Size by Region (2021-2026)
- 5.2.3 Metabotropic Glutamate Receptor 3 Forecasted Market Size by Region (2027-2032)
- 5.3 Metabotropic Glutamate Receptor 3 Market Dynamics
- 5.3.1 Metabotropic Glutamate Receptor 3 Industry Trends
- 5.3.2 Metabotropic Glutamate Receptor 3 Market Drivers
- 5.3.3 Metabotropic Glutamate Receptor 3 Market Challenges
- 5.3.4 Metabotropic Glutamate Receptor 3 Market Restraints
6 Market Competitive Landscape by Players
- 6.1 Global Top Metabotropic Glutamate Receptor 3 Players by Revenue
- 6.1.1 Global Top Metabotropic Glutamate Receptor 3 Players by Revenue (2021-2026)
- 6.1.2 Global Metabotropic Glutamate Receptor 3 Revenue Market Share by Players (2021-2026)
- 6.2 Global Metabotropic Glutamate Receptor 3 Industry Players Ranking, 2023 VS 2024 VS 2025
- 6.3 Global Key Players of Metabotropic Glutamate Receptor 3 Head Office and Area Served
- 6.4 Global Metabotropic Glutamate Receptor 3 Players, Product Type & Application
- 6.5 Global Metabotropic Glutamate Receptor 3 Manufacturers Established Date
- 6.6 Global Metabotropic Glutamate Receptor 3 Market CR5 and HHI
- 6.7 Global Players Mergers & Acquisition
7 North America
- 7.1 North America Metabotropic Glutamate Receptor 3 Market Size (2021-2032)
- 7.2 North America Metabotropic Glutamate Receptor 3 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 7.3 North America Metabotropic Glutamate Receptor 3 Market Size by Country (2021-2026)
- 7.4 North America Metabotropic Glutamate Receptor 3 Market Size by Country (2027-2032)
- 7.5 United States
- 7.5 United States
- 7.6 Canada
- 7.7 Mexico
8 Europe
- 8.1 Europe Metabotropic Glutamate Receptor 3 Market Size (2021-2032)
- 8.2 Europe Metabotropic Glutamate Receptor 3 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 8.3 Europe Metabotropic Glutamate Receptor 3 Market Size by Country (2021-2026)
- 8.4 Europe Metabotropic Glutamate Receptor 3 Market Size by Country (2027-2032)
- 8.5 Germany
- 8.6 France
- 8.7 U.K.
- 8.8 Italy
- 8.9 Spain
- 8.10 Russia
- 8.11 Netherlands
- 8.12 Nordic Countries
9 Asia-Pacific
- 9.1 Asia-Pacific Metabotropic Glutamate Receptor 3 Market Size (2021-2032)
- 9.2 Asia-Pacific Metabotropic Glutamate Receptor 3 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 9.3 Asia-Pacific Metabotropic Glutamate Receptor 3 Market Size by Country (2021-2026)
- 9.4 Asia-Pacific Metabotropic Glutamate Receptor 3 Market Size by Country (2027-2032)
- 9.5 China
- 9.6 Japan
- 9.7 South Korea
- 9.8 India
- 9.9 Australia
- 9.10 China Taiwan
- 9.11 Southeast Asia
10 South America
- 10.1 South America Metabotropic Glutamate Receptor 3 Market Size (2021-2032)
- 10.2 South America Metabotropic Glutamate Receptor 3 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 10.3 South America Metabotropic Glutamate Receptor 3 Market Size by Country (2021-2026)
- 10.4 South America Metabotropic Glutamate Receptor 3 Market Size by Country (2027-2032)
- 10.5 Brazil
- 10.6 Argentina
- 10.7 Chile
- 10.8 Colombia
- 10.9 Peru
11 Middle East & Africa
- 11.1 Middle East & Africa Metabotropic Glutamate Receptor 3 Market Size (2021-2032)
- 11.2 Middle East & Africa Metabotropic Glutamate Receptor 3 Market Growth Rate by Country: 2021 VS 2025 VS 2032
- 11.3 Middle East & Africa Metabotropic Glutamate Receptor 3 Market Size by Country (2021-2026)
- 11.4 Middle East & Africa Metabotropic Glutamate Receptor 3 Market Size by Country (2027-2032)
- 11.5 Saudi Arabia
- 11.6 Israel
- 11.7 United Arab Emirates
- 11.8 Turkey
- 11.9 Iran
- 11.10 Egypt
12 Players Profiled
- 12.1 Eli Lilly and Company
- 12.1.1 Eli Lilly and Company Company Information
- 12.1.2 Eli Lilly and Company Business Overview
- 12.1.3 Eli Lilly and Company Revenue in Metabotropic Glutamate Receptor 3 Business (2021-2026)
- 12.1.4 Eli Lilly and Company Metabotropic Glutamate Receptor 3 Product Portfolio
- 12.1.5 Eli Lilly and Company Recent Developments
- 12.2 Prexton Therapeutics SA
- 12.2.1 Prexton Therapeutics SA Company Information
- 12.2.2 Prexton Therapeutics SA Business Overview
- 12.2.3 Prexton Therapeutics SA Revenue in Metabotropic Glutamate Receptor 3 Business (2021-2026)
- 12.2.4 Prexton Therapeutics SA Metabotropic Glutamate Receptor 3 Product Portfolio
- 12.2.5 Prexton Therapeutics SA Recent Developments
- 12.3 Domain Therapeutics SA
- 12.3.1 Domain Therapeutics SA Company Information
- 12.3.2 Domain Therapeutics SA Business Overview
- 12.3.3 Domain Therapeutics SA Revenue in Metabotropic Glutamate Receptor 3 Business (2021-2026)
- 12.3.4 Domain Therapeutics SA Metabotropic Glutamate Receptor 3 Product Portfolio
- 12.3.5 Domain Therapeutics SA Recent Developments
- 12.4 Denovo Biopharma LLC
- 12.4.1 Denovo Biopharma LLC Company Information
- 12.4.2 Denovo Biopharma LLC Business Overview
- 12.4.3 Denovo Biopharma LLC Revenue in Metabotropic Glutamate Receptor 3 Business (2021-2026)
- 12.4.4 Denovo Biopharma LLC Metabotropic Glutamate Receptor 3 Product Portfolio
- 12.4.5 Denovo Biopharma LLC Recent Developments
- 12.5 Aevi Genomic Medicine Inc
- 12.5.1 Aevi Genomic Medicine Inc Company Information
- 12.5.2 Aevi Genomic Medicine Inc Business Overview
- 12.5.3 Aevi Genomic Medicine Inc Revenue in Metabotropic Glutamate Receptor 3 Business (2021-2026)
- 12.5.4 Aevi Genomic Medicine Inc Metabotropic Glutamate Receptor 3 Product Portfolio
- 12.5.5 Aevi Genomic Medicine Inc Recent Developments
- 12.6 Addex Therapeutics Ltd
- 12.6.1 Addex Therapeutics Ltd Company Information
- 12.6.2 Addex Therapeutics Ltd Business Overview
- 12.6.3 Addex Therapeutics Ltd Revenue in Metabotropic Glutamate Receptor 3 Business (2021-2026)
- 12.6.4 Addex Therapeutics Ltd Metabotropic Glutamate Receptor 3 Product Portfolio
- 12.6.5 Addex Therapeutics Ltd Recent Developments
13 Report Conclusion
14 Disclaimer
GET THE RESEARCH
Choose your license.
Choose who needs access.
All options are for this report and research series.
PDF by email within 3–5 working days after payment confirmation.
Talk to an analyst